

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Administrative Proceedings Rulings
Release No. 5057 / September 18, 2017

Administrative Proceeding
File No. 3-18141

In the Matter of

**CellCyte Genetics Corp.,
China Pediatric
Pharmaceuticals, Inc., and
Hawker Energy, Inc.**

**Order to Show Cause,
Postpone Hearing, and
Schedule Prehearing
Conference**

On August 28, 2017, the Securities and Exchange Commission issued an order instituting proceedings (OIP) pursuant to Section 12(j) of the Securities Exchange Act of 1934, alleging that Respondents have securities registered with the Commission and are delinquent in their periodic filings. The Commission accepted an offer of settlement submitted by Hawker Energy, Inc., and the proceeding against it has ended. *CellCyte Genetics Corp.*, Exchange Act Release No. 81621, 2017 SEC LEXIS 2865 (Sept. 14, 2017).

The Division of Enforcement submitted a declaration establishing that CellCyte Genetics was served with the OIP on August 31, 2017. 17 C.F.R. § 201.141(a)(2)(ii). CellCyte Genetics's answer was due September 13, 2017. OIP at 3; 17 C.F.R. §§ 201.160(b), .220(b). To date, it has not filed an answer. I ORDER CellCyte Genetics to SHOW CAUSE by September 28, 2017, why the registration of its securities should not be revoked by default due to its failure to file an answer or otherwise defend the proceeding. *See* OIP at 3; 17 C.F.R. §§ 201.155(a), .220(f).

The hearing scheduled for September 20, 2017, is POSTPONED. I will hold a telephonic prehearing conference on September 29, 2017, at 2:00 p.m., to discuss the resolution of this proceeding against CellCyte Genetics and the status of service of the OIP on China Pediatric Pharmaceuticals.

Brenda P. Murray
Chief Administrative Law Judge